$23.41−0.03 (−0.13%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
SI-BONE (SIBN) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~22.2%/yr (FY21→FY25), net margin −9.4%. Worth your attention in FY25: Share count (+29.6%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲20.2%
200.9
FY21→FY25CAGR +22.2%/yr
Net income ($M)▲38.8%
−18.9
FY21→FY25CAGR —
Free cash flow ($M)▲60.3%
−9.1
FY21→FY25CAGR —
Diluted EPS▲41.3%
−0.44
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+29.6%
33.1mn → 43.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$8.4M
−19.8% YoY in FY25 · 4.2% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-9¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 88.4% → 79.6%. Net margin -9.4% is below the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 220.7 | 200.9 | 167.2 | 138.9 | 106.4 | 90.2 | ▲20.2% | +22.2% |
Cost of revenue | 45.5 | 41.0 | 35.1 | 29.5 | 15.7 | 10.4 | ▲17.1% | +40.9% |
Gross profit | 175.2 | 159.9 | 132.1 | 109.4 | 90.7 | 79.7 | ▲21.0% | +19.0% |
Research & development | 18.3 | 17.4 | 16.6 | 15.0 | 13.6 | 12.4 | ▲5.4% | +8.8% |
Selling, general & admin | 40.1 | 40.5 | 33.8 | 31.1 | 29.0 | 25.1 | ▲20.1% | +12.8% |
Total operating expenses | 191.9 | 182.2 | 167.4 | 156.4 | 150.3 | 131.4 | ▲8.9% | +8.5% |
Operating incomefeeds ROC rank | −16.7 | −22.3 | −35.2 | −46.9 | −59.6 | −51.7 | ▲36.6% | — |
Other income, net | 3.0 | 3.4 | 4.3 | 3.6 | −1.5 | −4.9 | — | — |
Pretax income | −13.7 | −18.9 | −30.9 | −43.3 | −61.1 | −56.6 | ▲38.8% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −13.7 | −18.9 | −30.9 | −43.3 | −61.3 | −56.6 | ▲38.8% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.31 | −0.44 | −0.75 | −1.13 | −1.79 | −1.71 | ▲41.3% | — |
Diluted shares (mn) | 44.90 | 42.96 | 41.47 | 38.43 | 34.20 | 33.15 | ▲3.6% | +6.7% |
| Margins | ||||||||
Gross margin73rd pct in Healthcare | 79.4% | 79.6% | 79.0% | 78.8% | 85.2% | 88.4% | ▲0.5pp | −8.9pp |
Operating margin | −7.6% | −11.1% | −21.1% | −33.8% | −56.0% | −57.3% | ▲10.0pp | +46.2pp |
Net margin31st pct in Healthcare | −6.2% | −9.4% | −18.5% | −31.2% | −57.6% | −62.8% | ▲9.1pp | +53.3pp |
† TTM = trailing four quarters through 2026-09-30.
4 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was SI-BONE's revenue last fiscal year?
SI-BONE reported revenue of $200.9M in fiscal 2025, up 20.2% from fiscal 2024.
What was SI-BONE's net income?
SI-BONE reported net income of −$18.9M in fiscal 2025, a net margin of −9.4%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

